

GLAXOSMITHKLINE PLC  
Form 6-K  
February 26, 2009

**FORM 6-K**

**SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549**

**Report of Foreign Issuer**

**Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934**

For period ending February 2009

**GlaxoSmithKline plc**  
(Name of registrant)

**980 Great West Road, Brentford, Middlesex, TW8 9GS**  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the

Securities Exchange Act of 1934.

Yes No x

--

**Notifiable Share Interest in Octoplus N.V.**

GlaxoSmithKline plc (GSK) announces that on 25 February 2009, S.R. One, Limited, a wholly owned US-registered subsidiary of GSK ("S.R.One"), increased to 16.9% its interest in the issued ordinary share capital of OctoPlus N.V. ("OctoPlus"), a pharmaceuticals product and drug delivery company located in the Netherlands, and whose shares are traded on Euronext Amsterdam. GSK's interest, which is held entirely by S.R. One, now comprises 5,096,846 ordinary shares of OctoPlus.

This increased interest became disclosable under the rules of the Netherlands Authority for the Financial Markets ("AFM") upon reaching 15% of the issued share capital of OctoPlus, and an announcement regarding this increased holding is therefore due to be made to the AFM on 26 February 2009. The additional 3,115,012 ordinary shares in OctoPlus, which increased GSK's interest above the disclosable threshold and to its present holding, were acquired as a result of the conversion of an existing convertible loan between S.R. One and OctoPlus into ordinary shares of OctoPlus.

Simon Bicknell  
Company Secretary

26 February 2009

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

**GlaxoSmithKline plc**  
(Registrant)

Date: February 26 2009

By: VICTORIA WHYTE

-----

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc